A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumors
概览
- 阶段
- 1 期
- 干预措施
- ABBV-927
- 疾病 / 适应症
- Advanced Solid Tumors Cancer
- 发起方
- AbbVie
- 入组人数
- 163
- 试验地点
- 39
- 主要终点
- Time to Cmax (Tmax) of ABBV-181
- 状态
- 进行中（未招募）
- 最后更新
- 3个月前
概览
简要总结
This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.
研究者
入排标准
入选标准
- •Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to
- •Participants have adequate bone marrow, kidney and liver function.
- •Participants with a history of chronic heart failure or significant cardiovascular disease must have an echocardiogram or multigated acquisition scan indicating left ventricular ejection fraction greater than or equal to 45% within 28 days prior to the first dose of study drug.
- •Participants must have creatinine clearance greater than or equal to 50 mL/min as measured by 24-hour urine or estimated by the Cockcroft-Gault formula.
- •Participants must have total bilirubin less than or equal to 1.5 times the upper limit of normal (ULN), and aspartate aminotransferase and alanine aminotransferase less than or equal to 2.5 times ULN.
- •Participants in all monotherapy arms must have an advanced solid tumor that has progressed on standard therapies known to provide clinical benefit or the participants are intolerant to such therapies.
- •Participants in all combination therapy arms must have recurrent or metastatic HNSCC or NSCLC and previously received platinum-based therapy and progressed either during or after anti-programmed death ligand 1 (PDL1)-based therapy. In addition, participants must have received only one prior immunotherapy.
- •The Sponsor may decide to limit the specific tumor types selected or treatment settings for specific arms based on evidence gathered.
排除标准
- •Participant must not have an active or prior documented autoimmune disease in the last 2 years.
- •Participant must not have current or prior use of immunosuppressive medication within 14 days prior to the first dose (with certain exceptions).
- •Participant must not have a history of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic leukemia, solid organ transplantation, previous clinical diagnosis of tuberculosis, inflammatory bowel disease, interstitial lung disease, or immune-mediated pneumonitis.
- •Participant must not have a history of clinically significant uncontrolled condition(s) including but not limited to the following: uncontrolled hypertension; symptomatic congestive heart failure; unstable angina pectoris or cardiac arrhythmia including atrial fibrillation.
- •Participant must not have a history of coagulopathy or a platelet disorder associated with significant clinical risk of thromboembolic event in the judgement of the investigator, or major thromboembolic event within 6 months prior to the first dose of study treatment.
- •Participant must not have a prior grade greater than or equal to 3 immune-mediated neurotoxicity or pneumonitis while receiving immunotherapy.
- •Participant must not have a known uncontrolled malignancy of the central nervous system.
- •Participants in all combination therapy arms must not have a history of exposure to an immunotherapy experiencing an immune-mediated adverse event that required permanent discontinuation of the immunotherapy.
- •Female participants must not be pregnant, breastfeeding or considering becoming pregnant during the study or for at least 3 or 5 months (for monotherapy and combination therapy participants, respectively) after the last dose of study drug.
- •Male participants must not be considering fathering a child or donating sperm during the study or for at least 3 or 5 months (for monotherapy and combination therapy participants, respectively) after the last dose of study drug.
研究组 & 干预措施
Escalating Arm 1: ABBV-927
Participants with solid tumors will receive escalating intravenous (IV) doses of ABBV-927.
干预措施: ABBV-927
Escalating Arm 2: ABBV-927
Participants with solid tumors will receive escalating intratumoral (IT) doses of ABBV-927.
干预措施: ABBV-927
Escalating Arm 3: ABBV-927+ABBV-181
Participants with Non-Small Cell Lung Cancer (NSCLC) will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
干预措施: ABBV-927
Escalating Arm 3: ABBV-927+ABBV-181
Participants with Non-Small Cell Lung Cancer (NSCLC) will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
干预措施: ABBV-181
Escalating Arm 4: ABBV-927+ABBV-181
Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive escalating IT doses of ABBV-927 and IV doses of ABBV-181.
干预措施: ABBV-927
Escalating Arm 4: ABBV-927+ABBV-181
Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive escalating IT doses of ABBV-927 and IV doses of ABBV-181.
干预措施: ABBV-181
Escalating Arm 5 (Japan): ABBV-927
Participants with solid tumors will receive escalating intravenous (IV) doses of ABBV-927.
干预措施: ABBV-927
Escalating Arm 6 (Japan): ABBV-927+ABBV-181
Participants with solid tumors will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
干预措施: ABBV-927
Escalating Arm 6 (Japan): ABBV-927+ABBV-181
Participants with solid tumors will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
干预措施: ABBV-181
Expansion Arm A: ABBV-927
Additional participants with HNSCC or NSCLC will receive intravenous (IV) doses of ABBV-927.
干预措施: ABBV-927
Expansion Arm B: ABBV-927+ABBV-181
Additional participants with HNSCC will receive IT doses of ABBV-927 and IV doses of ABBV-181.
干预措施: ABBV-927
Expansion Arm B: ABBV-927+ABBV-181
Additional participants with HNSCC will receive IT doses of ABBV-927 and IV doses of ABBV-181.
干预措施: ABBV-181
Expansion Arm C: ABBV-927+ABBV-181
Additional participants with NSCLC will receive IV doses of ABBV-927 and IV doses of ABBV-181.
干预措施: ABBV-927
Expansion Arm C: ABBV-927+ABBV-181
Additional participants with NSCLC will receive IV doses of ABBV-927 and IV doses of ABBV-181.
干预措施: ABBV-181
结局指标
主要结局
Time to Cmax (Tmax) of ABBV-181
时间窗: Up to 12 weeks after participant's first dose
Time to Cmax (Tmax) of ABBV-181.
Maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181
时间窗: Up to 8 weeks
The MTD and the RPTD of ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 will be determined during the dose escalation phase of the study. Once the RPTD has been determined, the dose expansion portion will begin.
Area under the serum concentration-time curve (AUCt) of ABBV-927
时间窗: Up to 12 weeks after participant's first dose
Area under the serum concentration-time curve from time zero to the time of last measurable concentration (AUCt) of ABBV-927.
Terminal-Phase Elimination Rate Constant (β) of ABBV-181
时间窗: Up to 12 weeks after participant's first dose
Terminal-phase elimination rate constant (β)of ABBV-181.
Terminal half-life (t1/2) of ABBV-181
时间窗: Up to 4 weeks after participant's first dose
Terminal half-life (t1/2) of ABBV-181.
Area under the serum concentration-time curve (AUCt) of ABBV-181
时间窗: Up to 12 weeks after participant's first dose
Area under the serum concentration-time curve from time zero to the time of last measurable concentration (AUCt) of ABBV-181.
Time to Cmax (Tmax) of ABBV-927
时间窗: Up to 12 weeks after participant's first dose
Time to Cmax (Tmax) of ABBV-927.
Maximum observed serum concentration (Cmax) of ABBV-927
时间窗: Up to 12 weeks after participant's first dose
Maximum observed serum concentration (Cmax) of ABBV-927.
Terminal-Phase Elimination Rate Constant (β) of ABBV-927
时间窗: Up to 12 weeks after participant's first dose
Terminal-phase elimination rate constant (β)of ABBV-927.
Maximum observed serum concentration (Cmax) of ABBV-181
时间窗: Up to 12 weeks after participant's first dose
Maximum observed serum concentration (Cmax) of ABBV-181.
Terminal half-life (t1/2) of ABBV-927
时间窗: Up to 4 weeks after participant's first dose
Terminal half-life (t1/2) of ABBV-927.
Number of Participants with Adverse Events
时间窗: Up to 30 days after and up to 24-month of treatment period
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
次要结局
- Clinical benefit rate (CBR, defined as the percentage of participants with a confirmed partial, complete response, or stable disease for at least 24 weeks to the treatment)(Up to 30 days after and up to 24-month of treatment period)
- Progression-free survival (PFS)(Up to 30 days after and up to 24-month of treatment period)
- Objective response rate (ORR)(Up to 30 days after and up to 24-month of treatment period)
- Duration of objective response (DOR)(Up to 30 days after and up to 24-month of treatment period)